All In Biotech

Drug Trial Radar · NCT04704219

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants With First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

160

Actual

Start

Feb 23, 2021

Primary completion

Jan 27, 2025

Study completion Oct 21, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Eisai Inc.
First posted
Jan 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.

Conditions

  • Renal Cell Carcinoma

Interventions

  • PembrolizumabBiological

    Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.

  • LenvatinibDrug

    Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to approximately 47 months

Locations

56 sites in 14 countries. Site status is shown where the registry gives one.

  • Georgetown University Medical Center ( Site 0001)

    Washington D.C., District of Columbia

  • St. Vincent Frontier Cancer Center ( Site 0004)

    Billings, Montana

  • Comprehensive Cancer Centers of Nevada ( Site 0010)

    Las Vegas, Nevada

  • Memorial Sloan Kettering Cancer Center ( Site 0015)

    New York, New York

  • Fox Chase Cancer Center ( Site 0011)

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center ( Site 0008)

    Nashville, Tennessee

  • Seattle Cancer Care Alliance ( Site 0014)

    Seattle, Washington

  • MEDICAL COLLEGE OF WISCONSIN ( Site 0006)

    Milwaukee, Wisconsin

  • Macquarie University-MQ Health Clinical Trials Unit ( Site 0405)

    Macquarie Park, New South Wales, Australia

  • Calvary Mater Newcastle ( Site 0403)

    Waratah, New South Wales, Australia

  • Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si

    Brisbane, Queensland, Australia

  • Ashford Cancer Centre Research ( Site 0404)

    Kurralta Park, South Australia, Australia

  • Monash Health ( Site 0400)

    Clayton, Victoria, Australia

  • Fiona Stanley Hospital ( Site 0402)

    Murdoch, Western Australia, Australia

  • BC Cancer Vancouver-Clinical Trials Unit ( Site 1500)

    Vancouver, British Columbia, Canada

  • Sunnybrook Health Sciences Centre ( Site 1501)

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 1504)

    Toronto, Ontario, Canada

  • CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 1502)

    Québec, Quebec, Canada

  • Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1007)

    Strasbourg, Alsace, France

  • Centre François Baclesse ( Site 1000)

    Caen, Calvados, France

  • Centre de Cancérologie du Grand Montpellier ( Site 1005)

    Montpellier, Languedoc-Roussillon, France

  • centre hospitalier lyon sud ( Site 1003)

    Pierre-Bénite, Rhone, France

  • Gustave Roussy ( Site 1002)

    Villejuif, Val-de-Marne, France

  • Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0300)

    Debrecen, Hungary

  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás C

    Miskolc, Borsod-Abauj Zemplen county, Hungary

  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0303)

    Szolnok, Jász-Nagykun-Szolnok, Hungary

  • Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0304)

    Budapest, Pest County, Hungary

  • Tallaght University Hospital ( Site 1600)

    Dublin, Ireland

  • Azienda Ospedaliera Santa Maria Terni-SC Oncologia ( Site 0900)

    Terni, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 0901)

    Rome, Lazio, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0903)

    Milan, Lombardy, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Oncology Unit ( Site 0902)

    Verona, Veneto, Italy

  • Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-chemotherapy department ( Site 0800)

    Poznan, Greater Poland Voivodeship, Poland

  • Luxmed Onkologia sp. z o. o. ( Site 0802)

    Warsaw, Masovian Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

    Warsaw, Masovian Voivodeship, Poland

  • SHBI Leningrad Regional Clinical Oncology Dispensary-Clinical Trials Department ( Site 0607)

    Saint Petersburg, Russia

  • Russian Scientific Center of Radiology-Russian Scientific Center of Radiology ( Site 0602)

    Moscow, Moscow, Russia

  • Volga District Medical Center-Urology Department ( Site 0604)

    Nizhny Novgorod, Nizhny Novgorod Oblast, Russia

  • Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0605)

    Nizhny Novgorod, Nizhny Novgorod Oblast, Russia

  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1302)

    Seoul, South Korea

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.